Cargando…

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Ji, Chao, Cheng, Bo, Ruan, Shi-Fan, Liu, Tao, Huang, Jin-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752696/ https://www.ncbi.nlm.nih.gov/pubmed/33323821 http://dx.doi.org/10.1097/CM9.0000000000001259

Ejemplares similares

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety
por: Asawanonda, Pravit, et al.
Publicado: (2022)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Secukinumab in Erythrodermic Psoriasis: Real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites
por: Panda, Maitreyee, et al.
Publicado: (2021)

Reply to Callahan: Identifying “Real” Patients in the Real World
por: Dempsey, Timothy M.
Publicado: (2020)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
por: Ger, Tzong-Yun, et al.
Publicado: (2019)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
por: Strober, Bruce, et al.
Publicado: (2022)

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
por: Megna, Matteo, et al.
Publicado: (2022)

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study
por: Ding, Yangfeng, et al.
Publicado: (2023)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
por: Zheng, Yu-Xin, et al.
Publicado: (2022)

Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study
por: Nguyen, Hao T., et al.
Publicado: (2021)

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
por: Zhu, Si-Man, et al.
Publicado: (2020)

Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021)

Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records
por: Armstrong, April W., et al.
Publicado: (2021)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
por: Gottlieb, Alice B., et al.
Publicado: (2023)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
por: Chan, Yung, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
por: Jung, Seung-Won, et al.
Publicado: (2022)

Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study()
por: Oguz Topal, Ilteris, et al.
Publicado: (2022)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
por: Zhao, Yan, et al.
Publicado: (2021)

Artificial intelligence for malaria: Bridging the gap for real world usage
por: FAN, Bingwen Eugene, et al.
Publicado: (2022)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
por: Kiltz, Uta, et al.
Publicado: (2020)

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks
por: Chen, Xi‐Bei, et al.
Publicado: (2022)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases
por: Sun, Zhi-Lin, et al.
Publicado: (2020)

Secukinumab for Recalcitrant Chronic Plaque Psoriasis in a 9 Year Old Child
por: Shruthi, R, et al.
Publicado: (2021)

Real-world renal function among patients with multiple myeloma in the United States
por: Mikhael, Joseph, et al.
Publicado: (2021)

Real-world validation of the chemotherapy-induced nausea and vomiting predictive model and its optimization for identifying high-risk Chinese patients
por: Zhang, Linlin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_otlssa2jvtd518tccqlcphdcud